Drug Development

Caidya's union with Simbec-Orion isn't just another M&A deal. It’s a strategic play to build an end-to-end clinical partner for a complex global market.

Once a quiet niche, the wAIHA market is now a battleground for J&J, Sanofi, and Novartis, with a 14.4% growth forecast and a new class of drugs.

A new report reveals a massive strategic shift in obesity care. Pharma giants are pouring billions into FGF21, a new drug class aiming beyond weight loss.

Beyond a simple conference, Tsingke Biotech's recent salon was a strategic play to position itself as the linchpin in China's shift to biotech innovation.

Kowa's pemafibrate gets FDA Breakthrough status for a rare liver disease. We dissect what this means for patients, the science, and the company's global strategy.

A new collaboration between AustinPx and Thermo Fisher is scaling up KinetiSol, a breakthrough tech that makes insoluble drugs viable, promising greener paths to new therapies.

Millions suffer from chronic cough with no cure. A Boston biotech is testing a novel aerosol that targets the root cause, not just symptoms. Could it be the first disease-modifying treatment?

Artelo Biosciences uses advanced analytics to link its lead drug to a core disease pathway, a strategic move to de-risk development and attract major partners.

NurExone's modest C$628k funding isn't a sign of weakness, but a masterclass in biotech survival. It's a strategic play in a cautious market.

The world's only lupus-focused fund is betting on a new model blending VC rigor with patient-led strategy. But can this ambitious structure deliver real progress?

With a new U.S. patent, Quoin Pharmaceuticals reinforces its strategy for QRX003, a potential first-ever treatment for devastating Netherton Syndrome.

Sarepta seeks full FDA approval for two Duchenne drugs, leaning on real-world evidence after a key trial missed its goal. A test case for rare disease innovation.

Candel Therapeutics is betting its future on a pivotal Phase 3 trial for a novel viral immunotherapy, aiming to succeed where checkpoint inhibitors have failed.

New Phase 1 data suggests vamorolone delivers potent anti-inflammatory effects without the severe immunosuppression of traditional steroids at clinical doses.

With an $85M insider-led round and a seasoned M&A expert as CEO, Flare Therapeutics sharpens its focus on a novel prostate cancer drug, FX-111.

Vistagen's Phase 3 trial for its novel anxiety nasal spray fails its main goal, but a surprising signal in severe cases prompts a high-stakes pivot.

Allarity Therapeutics just secured a patent until 2042 for its cancer diagnostic. Is this the key to unlocking personalized treatment or a risky biotech bet?

New data reveals how Genelux’s oncolytic virus reawakens chemotherapy's power, offering a potential lifeline in a notoriously difficult-to-treat cancer.

Will Therapeutics lands $3.5M to develop the first targeted drug for anorexia, aiming to treat the biological roots of compulsion. A breakthrough in the making?